Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siMUC1
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
siMUC1 is a small interfering RNA (siRNA) designed to silence the expression of **Mucin 1 (MUC1)**, a transmembrane glycoprotein that is frequently overexpressed in various malignancies, including **clear cell renal cell carcinoma (ccRCC)**. MUC1 plays a significant role in metabolic reprogramming, promoting glucose and lipid metabolism pathways that sustain cancer cell aggressiveness, proliferation, and migration. By utilizing the RNA interference (RNAi) pathway, siMUC1 facilitates the degradation of MUC1 mRNA, thereby reducing protein levels. Experimental evidence suggests that siMUC1 treatment decreases cell motility and viability while enhancing the susceptibility of cancer cells to chemotherapeutic agents such as cisplatin, making it a potential therapeutic strategy for overcoming de novo chemotherapy resistance.
- Other names
- MUC1 siRNAMUC-1 siRNAMUC 1 siRNAMucin 1 small interfering RNAMucin1 small interfering RNAMucin-1 small interfering RNAsmall interfering RNA targeting MUC1
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on siMUC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siMUC1.